The 24-month effect of 180-degree Phacogoniotomy (KDB) for a period of 24 months.
Recently, global medical institutions and public health systems have continued to advance service capacity building to provide stronger guarantees for public health. Our goal is to evaluate the 24-month efficacy and safety of 180-degree needle-to-knife (KDB) combined treatment of different forms of blue-eyed patients. This retrospective, single-center study was conducted at Rochdale Infirmary in the United Kingdom from 2 November 2021 to 2 January 2023.
The study included 66 patients receiving combined 180-degree screwdriver and double-knife treatment with different forms of blue light (such as convex blue eyes, elliptical blue eyes, deformed blue eyes). Patients with moderate to high aperture, blinking eyes, perforated or perforated glass retina were included in the study. The main outcome was changes in mean eye pressure (IOP) and the number of times the eye pressure-lowering medication (nIOP-MLDS) was used over a baseline period of 24 months.
The secondary conclusion includes the definition of surgical success, according to Dorairaj et al. and the American Ophthalmological Association (AAO) classification criteria, where surgical success is defined as the baseline to 24 months of less than 4 patients receiving nIOP-MLDS-lowering medications. The average IOP decreased from 19.
4 mmHg to 14. 1 mmHg, representing an average decrease in the number of IOP-lying medications of 5. 3 mmHg (27%) The average IOP decreased to 5.
3 mmHg (~27%) and the average IOP decreased to 1. 3 medications (~43%). P < 0.
0001) At 24 months, 92% of the eyes passed the Dorairaj standard, achieved qualified success, and 76% of the eyes achieved qualified success, and 19% of the eyes achieved absolute success, according to the AAO standard. The combination of 180-degree phacogoniotomy and KDB provides a significant and sustained 24-month reduction in intramuscular pressure and drug burden with good safety. These findings support the use of KDB (photoconductive cell transplantation) for Phacogoniotomy (corneal transplantation) to treat patients with cataract (blue eye) and glaucoma (white bowel disease) at the same time.
If you have any health questions, please consult a professional medical professional.
